MDGL,SLRN Stock Price and Quote

Dollar change -8.07
Percentage change -2.41	%

Peers: GILD AKRO VKTX NBIX ENTA SLDB LXRX TSHA IMAB RDHL

| Held by: VTI IWM VB XBI VBR VXF IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-22.11	Insider Own	15.94%	Shs Outstand	22.00M	Perf Week	-5.75%
Market Cap	7.23B	Forward P/E	196.48	EPS next Y	1.67	Insider Trans	-2.16%	Shs Float	18.56M	Perf Month	-3.03%
Income	-465.89M	PEG	-	EPS next Q	-3.78	Inst Own	104.01%	Short Float	20.22%	Perf Quarter	2.02%
Sales	180.13M	P/S	40.12	EPS this Y	40.13%	Inst Trans	1.04%	Short Ratio	9.05	Perf Half Y	37.13%
Book/sh	34.28	P/B	9.55	EPS next Y	112.71%	ROA	-55.37%	Short Interest	3.75M	Perf Year	28.20%
Cash/sh	42.18	P/C	7.76	EPS next 5Y	-	ROE	-80.35%	52W Range	189.00 - 377.46	Perf YTD	6.08%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-32.06%	ROI	-53.37%	52W High	-13.28%	Beta	-0.69
Dividend TTM	-	Quick Ratio	5.90	Sales past 5Y	0.00%	Gross Margin	95.93%	52W Low	73.19%	ATR (14)	20.30
Dividend Ex-Date	-	Current Ratio	6.10	EPS Y/Y TTM	-10.89%	Oper. Margin	-276.39%	RSI (14)	48.88	Volatility	6.19% 5.56%
Employees	528	Debt/Eq	0.16	Sales Y/Y TTM	-	Profit Margin	-258.64%	Recom	1.29	Target Price	412.62
Option/Short	Yes / Yes	LT Debt/Eq	0.16	EPS Q/Q	52.28%	Payout	-	Rel Volume	0.98	Prev Close	335.39
Sales Surprise	4.27%	EPS Surprise	30.86%	Sales Q/Q	-	Earnings	Feb 26 BMO	Avg Volume	414.77K	Price	327.32
SMA20	-2.27%	SMA50	0.66%	SMA200	16.54%	Trades		Volume	396,116	Change	-2.41%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-28-25	Upgrade	B. Riley Securities	Neutral → Buy	$236 → $422
Feb-27-25	Reiterated	H.C. Wainwright	Buy	$400 → $405
Jun-28-24	Initiated	Cantor Fitzgerald	Neutral
Jun-11-24	Initiated	Wolfe Research	Outperform	$382
Apr-22-24	Initiated	BofA Securities	Underperform	$150
Mar-15-24	Upgrade	B. Riley Securities	Sell → Neutral	$155 → $270
Mar-06-24	Initiated	Citigroup	Buy	$382
Feb-26-24	Downgrade	B. Riley Securities	Neutral → Sell	$155
Dec-20-22	Reiterated	Oppenheimer	Outperform	$170 → $250
Dec-19-22	Upgrade	Raymond James	Underperform → Mkt Perform
Dec-19-22	Reiterated	Piper Sandler	Overweight	$203 → $280
Dec-19-22	Reiterated	H.C. Wainwright	Buy	$170 → $225
Jul-08-22	Downgrade	B. Riley Securities	Buy → Neutral	$131 → $75
Oct-07-21	Initiated	Jefferies	Buy	$151
Aug-06-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
May-20-21	Resumed	Goldman	Buy	$195
Nov-24-20	Resumed	Evercore ISI	Outperform	$180
Nov-06-20	Reiterated	H.C. Wainwright	Buy	$165 → $184
Jul-31-20	Initiated	Piper Sandler	Overweight	$208
Jun-05-20	Initiated	BMO Capital Markets	Market Perform	$135

Show Previous Ratings

Mar-11-25 08:00AM	Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors (GlobeNewswire)
Mar-07-25 05:35AM	Goldman Sachs Says Its Time to Pull the Trigger on Healthcare Stocks Here Are 2 Names to Pounce on Now (TipRanks)
Feb-28-25 10:20AM	Madrigal Pharmaceuticals price target raised to $239 from $154 at BofA (TipRanks)
Feb-27-25 02:05AM	Madrigal Pharmaceuticals Inc (MDGL) Q4 2024 Earnings Call Highlights: Strong Sales Growth and ... (GuruFocus.com) -5.66%
Feb-26-25 11:43PM	Q4 2024 Madrigal Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +14.99%
12:28PM	Loading…
12:28PM	Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis (Benzinga)
11:27AM	Why Madrigal Pharmaceuticals Stock Is Soaring Today (Motley Fool)
07:21AM	Madrigal: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra (resmetirom) in Patients with Compensated MASH Cirrhosis (GlobeNewswire)
06:30AM	Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra (resmetirom) in Patients with Compensated MASH Cirrhosis (GlobeNewswire)
Feb-21-25 08:00AM	Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-12-25 08:00AM	Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025 (GlobeNewswire)
Jan-17-25 08:28AM	Why Madrigal Pharmaceuticals Stock Was Plummeting This Week (Motley Fool) +7.64%
Jan-13-25 11:20AM	Why Madrigal Pharmaceuticals Stock Is Sinking Today (Motley Fool) -10.39%
06:45AM	Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra (GlobeNewswire)
08:00AM	Loading…
Jan-03-25 08:00AM	Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-06-24 06:46AM	Madrigal Pharmaceuticals price target raised to $427 from $415 at JMP Securities (TipRanks)
Nov-23-24 07:46AM	3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move (Motley Fool)
Nov-22-24 09:55AM	Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy? (Zacks) +5.53%
Nov-21-24 05:12PM	Why Is Madrigal Pharmaceuticals, Inc. (MDGL) Among the Worst Performing Biotech Stocks in 2024? (Insider Monkey)
Nov-18-24 02:53AM	The first MASH drug could open the door for others including GLP-1s (Pharma Voice) +5.17%
Nov-14-24 09:12PM	John Paulson's Strategic Moves in Q3 2024: A Focus on Anglogold Ashanti PLC (GuruFocus.com)
Nov-10-24 09:30AM	1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More (Motley Fool)
Nov-06-24 08:00AM	Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 09:55AM	Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectations (GuruFocus.com)
Nov-02-24 12:00PM	Madrigal, 89Bio jump after Novos semaglutide shows promise in MASH (TipRanks)
Nov-01-24 04:17PM	Madrigal Pharmaceuticals stock jumps on MASH drug hopes (Yahoo Finance Video) +23.23%
04:08PM	Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH (Investor's Business Daily)
03:03AM	Madrigal Pharmaceuticals Inc (MDGL) Q3 2024 Earnings Call Highlights: Strong Sales and ... (GuruFocus.com)
Oct-31-24 07:28AM	Madrigal: Q3 Earnings Snapshot (Associated Press Finance) +20.10%
07:00AM	Loading…
07:00AM	Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Oct-30-24 08:00AM	Madrigal Pharmaceuticals to Present Multiple Rezdiffra (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting (GlobeNewswire)
Oct-22-24 06:53AM	Madrigal Pharmaceuticals enrols patients in Phase III trial of NASH cirrhosis drug (Clinical Trials Arena)
Oct-21-24 08:00AM	Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis (GlobeNewswire)
Oct-18-24 08:00AM	Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024 (GlobeNewswire)
Oct-16-24 08:44AM	Madrigal Pharmaceuticals (MDGL): Leading the NASH Treatment Revolution with Rezdiffra (Insider Monkey)
Oct-02-24 08:00AM	Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor Conference (GlobeNewswire)
Oct-01-24 08:00AM	Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development (GlobeNewswire)
Sep-30-24 08:00AM	Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra (resmetirom) (GlobeNewswire)
Sep-25-24 12:03AM	Is Madrigal Pharmaceuticals, Inc. (MDGL) the Best Guru Stock To Buy Now? (Insider Monkey)
Aug-26-24 08:00AM	Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (GlobeNewswire)
Aug-17-24 10:15AM	Is Madrigal Pharmaceuticals Stock a Buy? (Motley Fool)
Aug-14-24 11:55PM	John Paulson's Strategic Exits and Key Investments in Q2 2024: Spotlight on Newmark Group Inc (GuruFocus.com)
06:00AM	This 1 Setback for Novo Nordisk Is Bullish for Madrigal Pharmaceuticals Stock (Motley Fool)
Aug-13-24 11:33AM	Madrigal plans to solidify Rezdiffras position in MASH despite start being slower than expected (Pharmaceutical Technology)
Aug-08-24 03:47AM	Q2 2024 Madrigal Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-24 04:14PM	Biotech Stocks: Why Acadia Pharma And Others Are Feeling 'Growing Pains' (Investor's Business Daily) -12.18%
11:12AM	Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line (Zacks)
07:20AM	Madrigal: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
06:30AM	Madrigals MASH drug launch gets off to a fast start (BioPharma Dive)
Aug-05-24 06:30AM	Is It Too Late to Buy Madrigal Pharmaceuticals Stock? (Motley Fool) -5.78%
Aug-02-24 07:00AM	Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel (GlobeNewswire)
Jul-24-24 08:00AM	Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024 (GlobeNewswire)
Jul-23-24 02:57PM	7 Biotech Stocks to Keep on Your Clinical Radar (InvestorPlace)
Jun-30-24 12:02PM	Is Madrigal Pharmaceuticals a Millionaire Maker? (Motley Fool)
Jun-28-24 06:45AM	Is Madrigal Pharmaceuticals Stock a Buy? (Motley Fool)
Jun-16-24 12:05PM	Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word. (Motley Fool)
Jun-15-24 09:45AM	Where Will Madrigal Pharmaceuticals Be in 3 Years? (Motley Fool)
Jun-12-24 03:56PM	Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade (Investor's Business Daily)
Jun-10-24 09:45AM	Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals (Motley Fool)
Jun-06-24 08:00AM	Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra (resmetirom) Presented at the EASL Congress (GlobeNewswire)
Jun-05-24 04:10PM	Madrigal, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH (Investor's Business Daily)
03:17PM	What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? (Benzinga)
10:56AM	Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH (Investor's Business Daily)
08:00AM	Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-29-24 08:00AM	Madrigal Pharmaceuticals to Present Multiple Rezdiffra (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress (GlobeNewswire)
May-24-24 03:17AM	Insider Sale at Madrigal Pharmaceuticals Inc (MDGL): Senior VP, Chief Pharmaceutical ... (GuruFocus.com)
May-21-24 09:45AM	Is Madrigal Pharmaceuticals Stock a Buy? (Motley Fool)
May-17-24 03:08AM	Madrigal Pharmaceuticals Insider Sold Shares Worth $4,787,404, According to a Recent SEC Filing (MT Newswires)
May-15-24 09:19PM	John Paulson's Strategic Moves in Q1 2024 Highlight Madrigal Pharmaceuticals' Prominent Role (GuruFocus.com)
May-10-24 08:51AM	B. Riley Cuts Madrigal Pharmaceuticals' Price Target to $200 From $270, Keeps Neutral Rating (MT Newswires)
May-09-24 10:53AM	UBS Adjusts Price Target on Madrigal Pharmaceuticals to $411 From $410, Maintains Buy Rating (MT Newswires)
May-08-24 01:23PM	Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:02AM	Madrigal Pharmaceuticals Inc (MDGL) (Q1 2024) Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-07-24 09:18AM	Sector Update: Health Care Stocks Steady Pre-Bell Tuesday (MT Newswires) -7.48%
08:34AM	Madrigal Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Rezdiffra Launch (GuruFocus.com)
08:08AM	Madrigal Pharmaceuticals Q1 Loss Widens; Shares Fall Pre-Bell (MT Newswires)
07:17AM	Madrigal: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Apr-24-24 04:00PM	Madrigal Statement on the Passing of Dr. Stephen Harrison (GlobeNewswire) -6.29% -5.02%
Apr-23-24 08:00AM	Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 (GlobeNewswire)
Apr-22-24 06:00AM	6 Stocks Positioned to Soar as Investors Focus on MASH (News Direct)
Apr-16-24 04:05PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-15-24 04:28PM	Latest Insider Selling in April 2024: 10 Stocks to Watch (Insider Monkey)
Apr-09-24 08:00AM	Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis (GlobeNewswire)
Apr-05-24 07:15AM	Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics (Motley Fool)
Apr-04-24 01:55AM	Madrigal Pharmaceuticals Inc Director James Daly Sells 32,489 Shares (GuruFocus.com)
01:54AM	Madrigal Pharmaceuticals Inc Director Richard Levy Sells 11,000 Shares (GuruFocus.com)
01:54AM	Madrigal Pharmaceuticals Inc Director Kenneth Bate Sells 32,489 Shares (GuruFocus.com)
Apr-03-24 04:05PM	Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:45AM	1 No-Brainer Growth Stock to Buy Now (Motley Fool)
Apr-01-24 09:09PM	The 3 Best Biotech Stocks to Buy in April 2024 (InvestorPlace)
09:59AM	ENDRA Life Sciences Inc. (NASDAQ:NDRA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 09:00AM	Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals (Motley Fool)
04:43AM	Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval? (Motley Fool)
Mar-26-24 09:53AM	Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock (Motley Fool)
Mar-22-24 06:15AM	This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy? (Motley Fool)
Mar-19-24 05:50AM	Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win? (Motley Fool) -6.20%
Mar-18-24 11:58PM	Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering (GlobeNewswire)

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on March 2000 and is headquartered in West Conshohocken, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Mar 05 '25	Option Exercise	87.49	14,113	1,234,766	17,841	Mar 07 05:40 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Mar 05 '25	Sale	341.32	14,113	4,817,104	3,728	Mar 07 05:40 PM
Kelley Shannon T	General Counsel	Mar 03 '25	Sale	335.00	415	139,025	7,290	Mar 05 04:36 PM
Dier Mardi	SVP and CFO	Mar 03 '25	Sale	324.96	1,961	637,248	6,914	Mar 05 04:31 PM
Huntsman Carole	Chief Commercial Officer	Mar 03 '25	Sale	325.98	1,834	597,840	8,604	Mar 05 04:24 PM
ROBERT WALTERMIRE	Officer	Mar 05 '25	Proposed Sale	341.32	14,113	4,817,104		Mar 05 04:07 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Feb 28 '25	Sale	341.07	1,227	418,488	3,728	Mar 04 09:24 PM
Mardi Dier	Officer	Mar 03 '25	Proposed Sale	325.89	1,187	386,834		Mar 03 08:27 PM
SHANNON KELLEY	Officer	Mar 03 '25	Proposed Sale	341.27	415	141,627		Mar 03 04:51 PM
CAROLE A HUNTSMAN	Officer	Mar 03 '25	Proposed Sale	341.27	1,834	625,889		Mar 03 04:12 PM
ROBERT WALTERMIRE	Officer	Feb 28 '25	Proposed Sale	341.07	1,227	418,488		Feb 28 04:59 PM
Daly James M	Director	Feb 27 '25	Option Exercise	82.90	15,470	1,282,478	17,382	Feb 28 04:31 PM
Daly James M	Director	Feb 27 '25	Sale	347.45	15,470	5,375,126	1,912	Feb 28 04:31 PM
BATE KENNETH	Director	Feb 27 '25	Option Exercise	66.26	20,000	1,325,287	21,912	Feb 28 04:30 PM
BATE KENNETH	Director	Feb 27 '25	Sale	356.44	20,000	7,128,759	1,912	Feb 28 04:30 PM
JAMES M DALY	Director	Feb 27 '25	Proposed Sale	347.45	15,470	5,375,126		Feb 27 04:54 PM
KENNETH M BATE	Director	Feb 27 '25	Proposed Sale	356.44	20,000	7,128,758		Feb 27 04:51 PM
Huntsman Carole	Chief Commercial Officer	Jan 24 '25	Sale	335.24	347	116,328	10,438	Jan 27 05:18 PM
Sibold William John	President and CEO	Jan 24 '25	Sale	335.24	1,584	531,020	54,303	Jan 27 05:12 PM
Taub Rebecca	Pres., R&D, and CMO	Jan 24 '25	Sale	335.24	648	217,236	456,662	Jan 27 05:07 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jan 24 '25	Sale	335.24	103	34,530	4,955	Jan 27 05:03 PM
Rebecca Taub	Officer	Jan 24 '25	Proposed Sale	340.14	648	220,411		Jan 24 06:00 PM
William John Sibold	Officer	Jan 24 '25	Proposed Sale	340.14	1,584	538,782		Jan 24 06:00 PM
Carole Huntsman	Officer	Jan 24 '25	Proposed Sale	340.14	347	118,029		Jan 24 06:00 PM
Robert E Waltermire	Officer	Jan 24 '25	Proposed Sale	340.14	103	35,034		Jan 24 06:00 PM
Kelley Shannon T	General Counsel	Jan 17 '25	Sale	273.41	277	75,735	7,705	Jan 17 07:10 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jan 17 '25	Sale	273.41	442	120,847	5,058	Jan 17 07:08 PM
Taub Rebecca	Pres., R&D, and CMO	Jan 17 '25	Sale	273.41	1,689	461,789	457,310	Jan 17 07:05 PM
Rebecca Taub	Officer	Jan 17 '25	Proposed Sale	272.79	1,689	460,742		Jan 17 05:30 PM
Shannon Kelley	Officer	Jan 17 '25	Proposed Sale	272.79	277	75,563		Jan 17 05:30 PM
Robert E Waltermire	Officer	Jan 17 '25	Proposed Sale	272.79	442	120,573		Jan 17 05:30 PM
CRAVES FRED B	Director	Dec 03 '24	Sale	315.31	3,600	1,135,122	11,000	Dec 05 04:46 PM
CRAVES FRED B	Director	Nov 25 '24	Sale	350.30	3,400	1,191,028	14,600	Nov 27 04:16 PM
CRAVES FRED B	Director	Nov 25 '24	Proposed Sale	322.73	10,000	3,227,300		Nov 25 04:10 PM
Huntsman Carole	Chief Commercial Officer	Nov 21 '24	Sale	316.92	688	218,041	10,785	Nov 22 04:30 PM
Carole Huntsman	Officer	Nov 21 '24	Proposed Sale	316.92	688	218,040		Nov 21 04:30 PM
Levy Richard S	Director	Nov 07 '24	Option Exercise	7.36	5,000	36,800	16,012	Nov 08 05:07 PM
Levy Richard S	Director	Nov 07 '24	Sale	350.00	5,000	1,750,000	11,012	Nov 08 05:07 PM
RICHARD S LEVY	Director	Nov 07 '24	Proposed Sale	338.22	5,000	1,691,100		Nov 07 04:36 PM
Levy Richard S	Director	Nov 01 '24	Option Exercise	7.36	5,000	36,800	16,012	Nov 05 07:01 PM
Levy Richard S	Director	Nov 01 '24	Sale	300.94	5,000	1,504,703	11,012	Nov 05 07:01 PM
RICHARD S LEVY	Director	Nov 01 '24	Proposed Sale	259.34	5,000	1,296,700		Nov 01 04:47 PM
Sibold William John	President and CEO	Sep 09 '24	Sale	243.83	6,363	1,551,490	55,887	Sep 11 09:51 PM
William John Sibold	Officer	Sep 09 '24	Proposed Sale	243.83	6,363	1,551,514		Sep 10 09:29 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jun 14 '24	Option Exercise	87.09	1,900	165,471	7,400	Jun 18 09:39 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jun 14 '24	Sale	280.00	1,900	532,000	5,500	Jun 18 09:39 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jun 12 '24	Option Exercise	87.92	2,000	175,840	7,500	Jun 14 09:44 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	Jun 12 '24	Sale	285.00	2,000	570,000	5,500	Jun 14 09:44 PM
Waltermire Robert E.	Senior VP, Chief Pharma Dev.	May 21 '24	Sale	231.34	1,036	239,668	5,500	May 23 09:36 PM
CRAVES FRED B	Director	May 14 '24	Option Exercise	103.02	22,489	2,316,844	435,851	May 16 09:53 PM
CRAVES FRED B	Director	May 14 '24	Sale	212.88	22,489	4,787,404	413,362	May 16 09:53 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 08 '24	Option Exercise	9.45	2,676	25,288	461,675	Apr 10 08:53 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 08 '24	Sale	245.99	2,676	658,258	458,999	Apr 10 08:53 PM
FRIEDMAN PAUL A	Director	Apr 08 '24	Option Exercise	9.45	26,270	248,251	212,005	Apr 10 08:50 PM
FRIEDMAN PAUL A	Director	Apr 08 '24	Sale	246.19	26,270	6,467,491	185,735	Apr 10 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 03 '24	Option Exercise	9.45	27,845	263,135	486,844	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 05 '24	Option Exercise	9.45	27,506	259,932	486,505	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 04 '24	Option Exercise	9.45	18,537	175,175	477,536	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 03 '24	Sale	245.14	27,845	6,825,976	458,999	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 05 '24	Sale	243.36	27,506	6,693,790	458,999	Apr 05 08:50 PM
Taub Rebecca	Pres., R&D, and CMO	Apr 04 '24	Sale	242.91	18,537	4,502,823	458,999	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 05 '24	Option Exercise	9.45	27,613	260,943	213,348	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 03 '24	Option Exercise	9.45	27,407	258,996	213,142	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 04 '24	Option Exercise	9.45	18,710	176,810	204,445	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 05 '24	Sale	243.40	27,613	6,721,081	185,735	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 03 '24	Sale	245.12	27,407	6,718,002	185,735	Apr 05 08:50 PM
FRIEDMAN PAUL A	Director	Apr 04 '24	Sale	242.96	18,710	4,545,721	185,735	Apr 05 08:50 PM
Levy Richard S	Director	Apr 01 '24	Option Exercise	63.92	11,000	703,160	21,298	Apr 03 08:47 PM
Levy Richard S	Director	Apr 01 '24	Sale	257.48	11,000	2,832,335	10,298	Apr 03 08:47 PM
BATE KENNETH	Director	Apr 01 '24	Option Exercise	57.96	21,277	1,233,187	22,475	Apr 03 08:44 PM
BATE KENNETH	Director	Apr 02 '24	Option Exercise	105.08	11,212	1,178,157	12,410	Apr 03 08:44 PM
BATE KENNETH	Director	Apr 01 '24	Sale	257.26	21,277	5,473,779	1,198	Apr 03 08:44 PM
BATE KENNETH	Director	Apr 02 '24	Sale	244.49	11,212	2,741,219	1,198	Apr 03 08:44 PM
Daly James M	Director	Apr 01 '24	Option Exercise	100.79	21,577	2,174,711	22,775	Apr 03 08:41 PM
Daly James M	Director	Apr 02 '24	Option Exercise	105.08	10,912	1,146,633	12,110	Apr 03 08:41 PM
Daly James M	Director	Apr 01 '24	Sale	257.24	21,577	5,550,544	1,198	Apr 03 08:41 PM
Daly James M	Director	Apr 02 '24	Sale	244.51	10,912	2,668,087	1,198	Apr 03 08:41 PM

MDGL

Madrigal Pharmaceuticals Inc

SLRN

Acelyrin Inc

Upgrade your FINVIZ experience